EMG
ANIP icon

Ellington Management Group’s ANI Pharmaceuticals ANIP Stock Holding History

Ellington Management Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-9,800
Closed -$650K – 537
2016
Q3 		$650K Buy
+9,800
New +$613K 0.18% 191

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Ellington Management Group's ANIP Position: Q4 2016 in Review

Ellington Management Group sold out of ANI Pharmaceuticals (ANIP) in Q4 2016, closing a stake of 9,800 shares — an estimated $650K sold.

Ellington Management Group first reported a position in ANIP in Q3 2016 and held it in 1 quarter. The position peaked at $650K in Q3 2016. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

  • Ellington Management Group reported no remaining ANI Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ellington Management Group sold 9,800 ANI Pharmaceuticals shares in Q4 2016, an estimated $650K.
  • Ellington Management Group first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Ellington Management Group's ANI Pharmaceuticals position peaked at $650K in Q3 2016.
  • 157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on Ellington Management Group's 13F filing for Q4 2016, filed 14 Feb 2017.